Previous 10 | Next 10 |
Albireo Pharma Inc. (NASDAQ:ALBO) traded at a new 52-week high today of $52.81. So far today approximately 9.3 million shares have been exchanged, as compared to an average 30-day volume of 327,000 shares. Albireo Pharma Inc is a commercial-stage biopharmaceutical company. It focuses on ...
– Phase 3 ASSERT study on track to report topline data by the end of year – Albireo launches Expanded Access Program (EAP) for Alagille syndrome patients BOSTON, March 29, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver...
This article focuses on the major influences towards a biotech company's share price, rather than their value or opportunity. These catalysts will be important to consider when timing your entry and exit points. This article will be the last that focuses on evaluating individual h...
Albireo Pharma, Inc. (ALBO) Q4 2021 Earnings Conference Call March 1, 2022 10:00 AM ET Company Participants Paul Arndt – Managing Director-LifeSci Advisors, LLC Ron Cooper – President and Chief Executive Officer Pamela Stephenson – Chief Commercial Officer Simon Harford &...
The following slide deck was published by Albireo Pharma, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Albireo Pharma, Inc. 2021 Q4 - Results - Earnings Call Presentation
Albireo Pharma press release (NASDAQ:ALBO): Q4 GAAP EPS of -$0.57. Revenue of $32.52M (vs $2.72M in Q420). For further details see: Albireo Pharma GAAP EPS of -$0.57, revenue of $32.52M
Bylvay™ (odevixibat) launched in the U.S. and Europe, 2021 product revenue, net $7 million NICE endorses clinical and economic benefits of Bylvay Phase 3 study in Alagille syndrome on track for readout in 2022 Reports $248.1 million of cash and cash eq...
Albireo Pharma (NASDAQ:ALBO) is scheduled to announce Q4 earnings results on Tuesday, March 1st, before market open. The consensus EPS Estimate is -$1.81 and the consensus Revenue Estimate is $11.1M (+308.1% Y/Y). For further details see: Albireo Pharma Q4 2021 Earnings Preview
ADT,AGEN,AKBA,ALBO,AMRN,AMRS,AXSM,AZO,OTCPK:BAYZF,BIDU,BLDR,BMO,BNS,BSY,CCCS,CHS,CMRX,CRON,DPZ,EHTH,EPZM,EVRI,FOUR,OTCQX:GTBIF,HGV,HOV,HRL,HTA,HZNP,IGT,IQ,ITCI,KSS,KTB,LILM,MANU,MCRB,MLCO,NFE,OTCQB:NLST,NUWE,OKE,PIRS,PLTK,PRGO,QTRX,REGI,RYTM,SE,SJM,TGT,TGTX,TLS,TWNK,UWMC,VFF,VRTV,WEN,WKHS,XXI...
BASEL, Switzerland, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the appointment of Michael Gutch, Ph.D., as Chief Financial Officer. Dr. Gutch has extensive experience in the hea...
News, Short Squeeze, Breakout and More Instantly...
Albireo Pharma Inc. Company Name:
ALBO Stock Symbol:
NASDAQ Market:
Bylvay (odevixibat) granted Priority Review by U.S. FDA ASSERT study demonstrated efficacy of Bylvay in pruritus, bile acids and sleep with a low drug-related diarrhea rate in Alagille patients Approval in second indication would more than double Bylvay market oppo...
Two somewhat under-the-radar biotech companies saw their share prices soar this week after agreeing to be acquired. CinCor Pharma (NASDAQ: CINC) is being bought out by deep-pocketed pharmaceutical company AstraZeneca , while Albireo Pharma (NASDAQ: ALBO) is set to be owned by ...
The Nasdaq Composite (NASDAQINDEX: ^IXIC) might finally be looking to gain some momentum in 2023, with investors desperately wanting a reversal from 2022's horrible performance. Sizable gains on Friday helped to build more positive sentiment, and the bullish move continued on Monday morni...